1887

Abstract

Human cytomegalovirus (HCMV) is a ubiquitous betaherpesvirus that causes life-threatening disease in immunocompromised and immunonaïve individuals. Type I interferons (IFNs) are crucial molecules in the innate immune response to HCMV and are also known to upregulate several components of the interchromosomal multiprotein aggregates collectively referred to as nuclear domain 10 (ND10). In the context of herpesvirus infection, ND10 components are known to restrict gene expression. This raises the question as to whether key ND10 components (PML, Sp100 and hDaxx) act as anti-viral IFN-stimulated genes (ISGs) during HCMV infection. In this study, analysis of ND10 component transcription during HCMV infection demonstrated that PML and Sp100 were significantly upregulated whilst hDaxx expression remained unchanged. In cells engineered to block the production of, or response to, type I IFNs, upregulation of PML and Sp100 was not detected during HCMV infection. Furthermore, pre-treatment with an IFN-β neutralizing antibody inhibited upregulation of PML and Sp100 during both infection and treatment with HCMV-infected cell supernatant. The significance of ND10 components functioning as anti-viral ISGs during HCMV infection was determined through knockdown of PML, Sp100 and hDaxx. ND10 knockdown cells were significantly more permissive to HCMV infection, as previously described but, in contrast to control cells, could support HCMV plaque formation following IFN-β pre-treatment. This ability of HCMV to overcome the potently anti-viral effects of IFN-β in ND10 expression deficient cells provides evidence that ND10 component upregulation is a key mediator of the anti-viral activity of IFN-β.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000858
2017-07-01
2020-01-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/7/1795.html?itemId=/content/journal/jgv/10.1099/jgv.0.000858&mimeType=html&fmt=ahah

References

  1. Seale H, Macintyre CR, Gidding HF, Backhouse JL, Dwyer DE et al. National serosurvey of cytomegalovirus in Australia. Clin Vaccine Immunol 2006;13:1181–1184 [CrossRef][PubMed]
    [Google Scholar]
  2. Cannon MJ. Congenital cytomegalovirus (CMV) epidemiology and awareness. J Clin Virol 2009;46:S6–S10 [CrossRef][PubMed]
    [Google Scholar]
  3. Morioka I, Sonoyama A, Tairaku S, Ebina Y, Nagamata S et al. Awareness of and knowledge about mother-to-child infections in Japanese pregnant women. Congenit Anom 2014;54:35–40 [CrossRef][PubMed]
    [Google Scholar]
  4. Cannon MJ, Westbrook K, Levis D, Schleiss MR, Thackeray R et al. Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus. Prev Med 2012;54:351–357 [CrossRef][PubMed]
    [Google Scholar]
  5. Wizman S, Lamarre V, Coic L, Kakkar F, Le Meur JB et al. Awareness of cytomegalovirus and risk factors for susceptibility among pregnant women, in Montreal, Canada. BMC Pregnancy Childbirth 2016;16:1–8 [CrossRef][PubMed]
    [Google Scholar]
  6. Slobedman B, Cao JZ, Avdic S, Webster B, Mcallery S et al. Human cytomegalovirus latent infection and associated viral gene expression. Future Microbiol 2010;5:883–900 [CrossRef][PubMed]
    [Google Scholar]
  7. Stern H. Isolation of cytomegalovirus and clinical manifestations of infection at different ages. Br Med J 1968;1:665–669 [CrossRef][PubMed]
    [Google Scholar]
  8. Pass RF, Zhang C, Evans A, Simpson T, Andrews W et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009;360:1191–1199 [CrossRef][PubMed]
    [Google Scholar]
  9. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989;261:3607–3609 [CrossRef][PubMed]
    [Google Scholar]
  10. Sison RF, Holland GN, Macarthur LJ, Wheeler NC, Gottlieb MS. Cytomegalovirus retinopathy as the initial manifestation of the acquired immunodeficiency syndrome. Am J Ophthalmol 1991;112:243–249 [CrossRef][PubMed]
    [Google Scholar]
  11. Reinke P, Prösch S, Kern F, Volk HD. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1999;1:157–164 [CrossRef][PubMed]
    [Google Scholar]
  12. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000;355:2032–2036 [CrossRef][PubMed]
    [Google Scholar]
  13. Bronke C, Palmer NM, Jansen CA, Westerlaken GH, Polstra AM et al. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 2005;191:873–880 [CrossRef][PubMed]
    [Google Scholar]
  14. Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol 2008;41:57–62 [CrossRef][PubMed]
    [Google Scholar]
  15. Nakamura K, Eizuru Y, Minamishima Y. Effect of natural human interferon-beta on the replication of human cytomegalovirus. J Med Virol 1988;26:363–373 [CrossRef][PubMed]
    [Google Scholar]
  16. Delannoy AS, Hober D, Bouzidi A, Wattre P. Role of interferon alpha (IFN-α) and interferon gamma (IFN-γ) in the control of the infection of monocyte-like cells with human cytomegalovirus (HCMV). Microbiol Immunol 1999;43:1087–1096 [CrossRef][PubMed]
    [Google Scholar]
  17. Sainz B, Lamarca HL, Garry RF, Morris CA. Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virol J 2005;2:14 [CrossRef][PubMed]
    [Google Scholar]
  18. Mcsharry BP, Forbes SK, Avdic S, Randall RE, Wilkinson GW et al. Abrogation of the interferon response promotes more efficient human cytomegalovirus replication. J Virol 2015;89:1479–1483 [CrossRef][PubMed]
    [Google Scholar]
  19. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481–485 [CrossRef][PubMed]
    [Google Scholar]
  20. Schoggins JW, Macduff DA, Imanaka N, Gainey MD, Shrestha B et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 2014;505:691–695 [CrossRef][PubMed]
    [Google Scholar]
  21. Adamson AL, Kenney S. Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol 2001;75:2388–2399 [CrossRef][PubMed]
    [Google Scholar]
  22. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T et al. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 2006;80:7995–8005 [CrossRef][PubMed]
    [Google Scholar]
  23. Kyratsous CA, Silverstein SJ. Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J Virol 2009;83:4262–4274 [CrossRef][PubMed]
    [Google Scholar]
  24. Marcos-Villar L, Lopitz-Otsoa F, Gallego P, Muñoz-Fontela C, González-Santamaría J et al. Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J Virol 2009;83:8849–8858 [CrossRef][PubMed]
    [Google Scholar]
  25. Reichelt M, Wang L, Sommer M, Perrino J, Nour AM et al. Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog 2011;7:e1001266 [CrossRef][PubMed]
    [Google Scholar]
  26. Glass M, Everett RD. Components of promyelocytic leukemia nuclear bodies (ND10) act cooperatively to repress herpesvirus infection. J Virol 2013;87:2174–2185 [CrossRef][PubMed]
    [Google Scholar]
  27. Scherer M, Otto V, Stump JD, Klingl S, Müller R et al. Characterization of recombinant human cytomegaloviruses encoding IE1 mutants L174P and 1-382 reveals that viral targeting of PML bodies perturbs both intrinsic and innate immune responses. J Virol 2015;90:1190–1205 [CrossRef][PubMed]
    [Google Scholar]
  28. Tavalai N, Adler M, Scherer M, Riedl Y, Stamminger T. Evidence for a dual antiviral role of the major nuclear domain 10 component Sp100 during the immediate-early and late phases of the human cytomegalovirus replication cycle. J Virol 2011;85:9447–9458 [CrossRef][PubMed]
    [Google Scholar]
  29. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J Virol 2006;80:8006–8018 [CrossRef][PubMed]
    [Google Scholar]
  30. Tavalai N, Papior P, Rechter S, Stamminger T. Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. J Virol 2008;82:126–137 [CrossRef][PubMed]
    [Google Scholar]
  31. Landolfo S, de Andrea M, dell'oste V, Gugliesi F. Intrinsic host restriction factors of human cytomegalovirus replication and mechanisms of viral escape. World J Virol 2016;5:87–96 [CrossRef][PubMed]
    [Google Scholar]
  32. Saffert RT, Kalejta RF. Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. J Virol 2006;80:3863–3871 [CrossRef][PubMed]
    [Google Scholar]
  33. Saffert RT, Kalejta RF. Human cytomegalovirus gene expression is silenced by Daxx-mediated intrinsic immune defense in model latent infections established in vitro. J Virol 2007;81:9109–9120 [CrossRef][PubMed]
    [Google Scholar]
  34. Woodhall DL, Groves IJ, Reeves MB, Wilkinson G, Sinclair JH. Human Daxx-mediated repression of human cytomegalovirus gene expression correlates with a repressive chromatin structure around the major immediate early promoter. J Biol Chem 2006;281:37652–37660 [CrossRef][PubMed]
    [Google Scholar]
  35. Ascoli CA, Maul GG. Identification of a novel nuclear domain. J Cell Biol 1991;112:785–795 [CrossRef][PubMed]
    [Google Scholar]
  36. Bernardi R, Pandolfi PP, Structure PPP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007;8:1006–1016 [CrossRef][PubMed]
    [Google Scholar]
  37. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N et al. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 1999;147:221–234 [CrossRef][PubMed]
    [Google Scholar]
  38. Fu C, Ahmed K, Ding H, Ding X, Lan J et al. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene 2005;24:5401–5413 [CrossRef][PubMed]
    [Google Scholar]
  39. Cuchet-Lourenço D, Boutell C, Lukashchuk V, Grant K, Sykes A et al. SUMO pathway dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog 2011;7:e1002123 [CrossRef][PubMed]
    [Google Scholar]
  40. Dellaire G, Farrall R, Bickmore WA. The Nuclear Protein Database (NPD): sub-nuclear localisation and functional annotation of the nuclear proteome. Nucleic Acids Res 2003;31:328–330 [CrossRef][PubMed]
    [Google Scholar]
  41. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007;8:1006–1016 [CrossRef][PubMed]
    [Google Scholar]
  42. Lehming N, Le Saux A, Schüller J, Ptashne M. Chromatin components as part of a putative transcriptional repressing complex. Proc Natl Acad Sci USA 1998;95:7322–7326 [CrossRef][PubMed]
    [Google Scholar]
  43. Seeler JS, Marchio A, Sitterlin D, Transy C, Dejean A. Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc Natl Acad Sci USA 1998;95:7316–7321 [CrossRef][PubMed]
    [Google Scholar]
  44. Wu WS, Vallian S, Seto E, Yang WM, Edmondson D et al. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 2001;21:2259–2268 [CrossRef][PubMed]
    [Google Scholar]
  45. Hollenbach AD, Mcpherson CJ, Mientjes EJ, Iyengar R, Grosveld G. Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J Cell Sci 2002;115:3319–3330[PubMed]
    [Google Scholar]
  46. Xue Y, Gibbons R, Yan Z, Yang D, Mcdowell TL et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci USA 2003;100:10635–10640 [CrossRef][PubMed]
    [Google Scholar]
  47. Wilcox KW, Sheriff S, Isaac A, Taylor JL. SP100B is a repressor of gene expression. J Cell Biochem 2005;95:352–365 [CrossRef][PubMed]
    [Google Scholar]
  48. Chelbi-Alix MK, de Thé H. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 1999;18:935–941 [CrossRef][PubMed]
    [Google Scholar]
  49. Adler M, Tavalai N, Müller R, Stamminger T. Human cytomegalovirus immediate-early gene expression is restricted by the nuclear domain 10 component Sp100. J Gen Virol 2011;92:1532–1538 [CrossRef][PubMed]
    [Google Scholar]
  50. Kim YE, Lee JH, Kim ET, Shin HJ, Gu SY et al. Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression. J Virol 2011;85:11928–11937 [CrossRef][PubMed]
    [Google Scholar]
  51. Scherer M, Wagenknecht N, Reuter N, Stamminger T. Silencing of human cytomegalovirus gene expression mediated by components of pml nuclear bodies. In Doerfler W, Böhm P. (editors) Epigenetics - A Different Way of Looking at Genetics Cham: Springer International Publishing; 2016; pp.175–196[CrossRef]
    [Google Scholar]
  52. Kelly C, van Driel R, Wilkinson GW. Disruption of PML-associated nuclear bodies during human cytomegalovirus infection. J Gen Virol 1995;76:2887–2893 [CrossRef][PubMed]
    [Google Scholar]
  53. Ahn JH, Hayward GS. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J Virol 1997;71:4599–4613[PubMed]
    [Google Scholar]
  54. Ahn JH, Hayward GS. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection. Virology 2000;274:39–55 [CrossRef][PubMed]
    [Google Scholar]
  55. Hofmann H, Sindre H, Stamminger T. Functional interaction between the pp71 protein of human cytomegalovirus and the PML-interacting protein human Daxx. J Virol 2002;76:5769–5783 [CrossRef][PubMed]
    [Google Scholar]
  56. Cantrell SR, Bresnahan WA. Human cytomegalovirus (HCMV) UL82 gene product (pp71) relieves hDaxx-mediated repression of HCMV replication. J Virol 2006;80:6188–6191 [CrossRef][PubMed]
    [Google Scholar]
  57. Hwang J, Kalejta RF. Human cytomegalovirus protein pp71 induces Daxx SUMOylation. J Virol 2009;83:6591–6598 [CrossRef][PubMed]
    [Google Scholar]
  58. Maul GG, Negorev D. Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle. Med Microbiol Immunol 2008;197:241–249 [CrossRef][PubMed]
    [Google Scholar]
  59. Guldner HH, Szostecki C, Grötzinger T, Will H. IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J Immunol 1992;149:4067–4073[PubMed]
    [Google Scholar]
  60. Chelbi-Alix MK, Pelicano L, Quignon F, Koken MH, Venturini L et al. Induction of the PML protein by interferons in normal and APL cells. Leukemia 1995;9:2027–2033[PubMed]
    [Google Scholar]
  61. Lavau C, Marchio A, Fagioli M, Jansen J, Falini B et al. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 1995;11:871–876[PubMed]
    [Google Scholar]
  62. Grötzinger T, Sternsdorf T, Jensen K, Will H. Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). Eur J Biochem 1996;238:554–560 [CrossRef][PubMed]
    [Google Scholar]
  63. Haugh KA, Shalginskikh N, Nogusa S, Skalka AM, Katz RA et al. The interferon-inducible antiviral protein Daxx is not essential for interferon-mediated protection against avian sarcoma virus. Virol J 2014;11:100–105 [CrossRef][PubMed]
    [Google Scholar]
  64. Zhu H, Cong JP, Shenk T. Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: induction of interferon-responsive RNAs. Proc Natl Acad Sci USA 1997;94:13985–13990 [CrossRef][PubMed]
    [Google Scholar]
  65. Boldogh I, Abubakar S, Albrecht T. Activation of proto-oncogenes: an immediate early event in human cytomegalovirus infection. Science 1990;247:561–564 [CrossRef][PubMed]
    [Google Scholar]
  66. Boldogh I, Abubakar S, Millinoff D, Deng CZ, Albrecht T. Cellular oncogene activation by human cytomegalovirus. Lack of correlation with virus infectivity and immediate early gene expression. Arch Virol 1991;118:163–177 [CrossRef][PubMed]
    [Google Scholar]
  67. Taylor RT, Bresnahan WA. Human cytomegalovirus immediate-early 2 gene expression blocks virus-induced beta interferon production. J Virol 2005;79:3873–3877 [CrossRef][PubMed]
    [Google Scholar]
  68. Boehme KW, Singh J, Perry ST, Compton T. Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. J Virol 2004;78:1202–1211 [CrossRef][PubMed]
    [Google Scholar]
  69. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol 2006;177:7094–7102 [CrossRef][PubMed]
    [Google Scholar]
  70. Defilippis VR, Robinson B, Keck TM, Hansen SG, Nelson JA et al. Interferon regulatory factor 3 is necessary for induction of antiviral genes during human cytomegalovirus infection. J Virol 2006;80:1032–1037 [CrossRef][PubMed]
    [Google Scholar]
  71. Mcsharry BP, Forbes SK, Cao JZ, Avdic S, Machala EA et al. Human cytomegalovirus upregulates expression of the lectin galectin 9 via induction of beta interferon. J Virol 2014;88:10990–10994 [CrossRef][PubMed]
    [Google Scholar]
  72. Hilton L, Moganeradj K, Zhang G, Chen YH, Randall RE et al. The NPro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation. J Virol 2006;80:11723–11732 [CrossRef][PubMed]
    [Google Scholar]
  73. Andrejeva J, Young DF, Goodbourn S, Randall RE. Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons. J Virol 2002;76:2159–2167 [CrossRef][PubMed]
    [Google Scholar]
  74. Taylor RT, Bresnahan WA. Human cytomegalovirus immediate-early 2 gene expression blocks virus-induced beta interferon production. J Virol 2005;79:3873–3877 [CrossRef][PubMed]
    [Google Scholar]
  75. Defilippis VR, Alvarado D, Sali T, Rothenburg S, Früh K. Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. J Virol 2010;84:585–598 [CrossRef][PubMed]
    [Google Scholar]
  76. Everett RD, Parada C, Gripon P, Sirma H, Orr A. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J Virol 2008;82:2661–2672 [CrossRef][PubMed]
    [Google Scholar]
  77. Bishop CL, Ramalho M, Nadkarni N, May Kong W, Higgins CF et al. Role for centromeric heterochromatin and PML nuclear bodies in the cellular response to foreign DNA. Mol Cell Biol 2006;26:2583–2594 [CrossRef][PubMed]
    [Google Scholar]
  78. Dağ F, Dölken L, Holzki J, Drabig A, Weingärtner A et al. Reversible silencing of cytomegalovirus genomes by type I interferon governs virus latency. PLoS Pathog 2014;10:e1003962 [CrossRef][PubMed]
    [Google Scholar]
  79. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778–809 [CrossRef][PubMed]
    [Google Scholar]
  80. Browne EP, Wing B, Coleman D, Shenk T. Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J Virol 2001;75:12319–12330 [CrossRef][PubMed]
    [Google Scholar]
  81. Netterwald JR, Jones TR, Britt WJ, Yang SJ, Mccrone IP et al. Postattachment events associated with viral entry are necessary for induction of interferon-stimulated genes by human cytomegalovirus. J Virol 2004;78:6688–6691 [CrossRef][PubMed]
    [Google Scholar]
  82. Simmen KA, Singh J, Luukkonen BG, Lopper M, Bittner A et al. Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Proc Natl Acad Sci USA 2001;98:7140–7145 [CrossRef][PubMed]
    [Google Scholar]
  83. Zhu H, Cong JP, Mamtora G, Gingeras T, Shenk T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc Natl Acad Sci USA 1998;95:14470–14475 [CrossRef][PubMed]
    [Google Scholar]
  84. Buonamici S, Li D, Mikhail FM, Sassano A, Platanias LC et al. EVI1 abrogates interferon-α response by selectively blocking PML induction. J Biol Chem 2005;280:428–436 [CrossRef][PubMed]
    [Google Scholar]
  85. Kim YE, Ahn JH. Positive role of promyelocytic leukemia protein in type I interferon response and its regulation by human cytomegalovirus. PLoS Pathog 2015;11:e1004785 [CrossRef][PubMed]
    [Google Scholar]
  86. El Asmi F, Maroui MA, Dutrieux J, Blondel D, Nisole S et al. Implication of PMLIV in both intrinsic and innate immunity. PLoS Pathog 2014;10:e1003975 [CrossRef][PubMed]
    [Google Scholar]
  87. Kim YJ, Kim ET, Kim YE, Lee MK, Kwon KM et al. Consecutive Inhibition of ISG15 expression and ISGylation by cytomegalovirus regulators. PLoS Pathog 2016;12:e1005850 [CrossRef][PubMed]
    [Google Scholar]
  88. Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O et al. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 2010;120:3191–3208 [CrossRef][PubMed]
    [Google Scholar]
  89. Gibson W. Structure and formation of the cytomegalovirus virion. Curr Top Microbiol Immunol 2008;325:187–204[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000858
Loading
/content/journal/jgv/10.1099/jgv.0.000858
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error